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Abstract
Background: It is unclear whether dengue serotypes differ in their propensity to cause severe disease. We analyzed
differences in serotype-specific disease severity in children presenting for medical attention in Bangkok, Thailand.
Methodology/Principal Findings: Prospective studies were conducted from 1994 to 2006. Univariate and multivariate
logistic and multinomial logistic regressions were used to determine if dengue hemorrhagic fever (DHF) and signs of severe
clinical disease (pleural effusion, ascites, thrombocytopenia, hemoconcentration) were associated with serotype. Crude and
adjusted odds ratios were calculated. There were 162 (36%) cases with DENV-1, 102 (23%) with DENV-2, 123 (27%) with
DENV-3, and 64 (14%) with DENV-4. There was no significant difference in the rates of DHF by serotype: DENV-2 (43%),
DENV-3 (39%), DENV-1 (34%), DENV-4 (31%). DENV-2 was significantly associated with increased odds of DHF grade I
compared to DF (OR 2.9 95% CI 1.1, 8.0), when using DENV-1 as the reference. Though not statistically significant, DENV-2
had an increased odds of total DHF and DHF grades II, III, and IV. Secondary serologic response was significantly associated
with DHF (OR 6.2) and increased when considering more severe grades of DHF. DENV-2 (9%) and -4 (3%) were significantly
less often associated with primary disease than DENV-1 (28%) and -3 (33%). Restricting analysis to secondary cases, we
found DENV-2 and DENV-3 to be twice as likely to result in DHF as DEN-4 (p=0.05). Comparing study years, we found the
rate of DHF to be significantly less in 1999, 2000, 2004, and 2005 than in 1994, the study year with the highest percentage of
DHF cases, even when controlling for other variables.
Conclusions/Significance: As in other studies, we find secondary disease to be strongly associated with DHF and with
more severe grades of DHF. DENV-2 appears to be marginally associated with more severe dengue disease as evidenced
by a significant association with DHF grade I when compared to DENV-1. In addition, we found non-significant trends with
other grades of DHF. Restricting the analysis to secondary disease we found DENV-2 and -3 to be twice as likely to result in
DHF as DEN-4. Differences in severity by study year may suggest that other factors besides serotype play a role in disease
severity.
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Introduction
Dengue virus (DENV) is an increasing problem in tropical and
sub-tropical countries, where Aedes spp mosquitoes transmit the
virus primarily in urban or semi-urban settings. Infection with
DENV may result in a sub-clinical infection, undifferentiated
fever, dengue fever (DF), dengue hemorrhagic fever (DHF), or
dengue shock syndrome (DSS)
[1]. Clinical manifestations of DF
commonly include fever, rash, hemorrhagic symptoms, headache,
ocular pain, arthralgia, myalgia, nausea, and vomiting
[2–4]. DHF
is difficult to differentiate from DF in the early stages of infection
and illness
[4,5]. The criteria that differentiate DHF from DF are
plasma leakage confirmed by pleural effusion, ascites, and/or
hemoconcentration (.20% above patient’s baseline), and throm-
bocytopenia (,100,000/mm
3)
[2].
While access to care, quality of interventions
[6], host genetic
factors
[7,8], and previous exposure to DENV
[9,10] are all known to
affect outcome, it is not entirely understood why some individuals
develop more severe disease. It has been well established that
secondary infections and infections in infants with non-neutralizing
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DHF
[11–14]. Host genetic determinants of disease severity have
been reported, including evidence that black patients may have a
lower incidence of DHF compared to other patients
[15–17]. Some
research has indicated that children are more susceptible to
developing DHF than adults
[2,12,18,19].
It has been observed that different dengue serotypes, and even
strains of the same serotype, differ in their propensity to cause
severe disease
[20,21]. However, there is no clear consensus on the
association of DHF and severe disease with serotype. Earlier
analyses of data collected during various DF and DHF outbreaks
worldwide have shown associations of DENV-2
[10,11,22–24] and
DENV-3
[13,21] with increased risk of hospitalization and severe
disease. Small sample sizes, lack of all four serotypes, inconsisten-
cies in findings, and short study durations are weaknesses of these
studies. Rico-Hesse et al. proposed that virulence of genotypes
within serotypes differs, as evidenced by the failure of American
DENV-2 in Latin America to produce DHF and the subsequent
increase in DHF with the introduction of a Southeast Asian strain
of DENV-2
[20]. However, neutralization of American DENV-2
by DENV-1 antibodies may have accounted for the absence of
DHF in these cases
[25,26].
We conducted an analysis of data collected at the Queen Sirikit
Institute of Child Health (QSNICH) in Bangkok, Thailand to
assess whether there were significant differences in severity of
disease between the four DENV serotypes in a pediatric
population after adjusting for other known risk factors. All four
serotypes were encountered, there was consistent application of
diagnostic criteria over multiple years, and care was guided by
WHO recommendations.
Methods
Study Site
A prospective observational study of dengue disease in children
at the QSNICH was conducted from 1994–1997, 1999–2002, and
2004–2006 collaboratively by QSNICH, the Armed Forces
Research Institute of Medical Science (AFRIMS), and the
University of Massachusetts Medical School. QSNICH is a Thai
Ministry of Health facility with 538 beds, including a DHF unit
with 30 beds and a dengue holding unit with approximately 20
beds. The hospital is a World Health Organization Collaborating
Center for Case Management of Dengue.
Study Population and Data Collection
The clinical study design has been reported previously
[27].
Briefly, children who presented to the outpatient department or
who had already been admitted to the hemorrhagic fever ward
were considered for study enrollment based on the following
criteria: oral temperature $37.5uC or rectal temperature
$38.5uC; history of fever for ,72 hours; no obvious source of
infection; weight .6 kg; and age 6 months through 15 years.
Exclusion criteria included presentation with clinical signs of
shock; or serious chronic disease (thalassemia, nephrosis or
nephrotic syndrome, cirrhosis, or malignancy). Due to staffing
limitations, only six cases per week could be enrolled. The
sampling methods were the same throughout the entire period.
We perform all the dengue diagnostic testing for the hospital and
found the percentages of each serotype (over the same time period)
within 3% of those in the study suggesting no bias in serotype
inclusion from the sampling.
Children were monitored as in-patients on the dengue ward,
where vital signs and weight were routinely measured. Blood for
serologic and clinical studies was drawn each morning for a
maximum of five consecutive days while the patient was febrile
and on the day following defervescence. A follow-up sample for
serological diagnosis was obtained from each child five to ten days
after discharge. Plasma leakage was assessed for each patient with
chest x-ray, physical exam, and hematocrit changes
[28];
ultrasound has been studied in a subset of this population, but
was not used in this study to classify patients as having ascites,
pleural effusion, or DHF. The clinical management of study
subjects was directed by the same physician for the study duration.
This study was approved by Human Use Review Committee of
the Walter Reed Army Institute of Research, Human Subjects
Research Review Board for the Commanding General of the
U.S. Army Medical Research and Material Command, Univer-
sity of Massachusetts Medical School IRB, the Thai Ministry of
Public Health’s Ethical Review Committee for Research in
Human Subjects, and the QSNICH IRB. Written informed
consent was obtained from the legal guardian of each participant.
Secondary data analysis at Mahidol Oxford Tropical Medicine
Research Unit and Johns Hopkins University was performed
using de-identified data, hence was not deemed human subjects
research.
Definitions
The outcomes of interest were DHF, DF, and DHF severity
grades (I–IV). Although outcomes were directed by WHO
guidelines, the physician considered the patient’s clinical course
and treatment in determining final clinical outcomes. Additional
outcomes included in the analysis were pleural effusion [measured
as both a binary variable and a continuous variable, the pleural
effusion index (‘‘PEI’’=1006 (maximum width of right pleural
effusion)/(maximum width of right hemithorax))]
[28], ascites,
thrombocytopenia, and hemoconcentration. Explanatory variables
used were age, sex, study year, blood type, serological response
profile (primary vs. secondary infection), and viral serotype.
Dengue EIA results were classified as primary if anti-dengue IgM
was greater than or equal to 40 units and anti-dengue IgM:anti-
IgG ratio was greater than or equal to 1.8. Results were classified
as secondary if anti-dengue IgM was greater than or equal to 40
units and anti-dengue IgM:anti-IgG ratio was less than 1.8
[29].
The case definition for DHF included acute febrile illness;
hemorrhagic manifestations (positive tourniquet test, petechiae,
Author Summary
The four dengue viruses (DENV) represent the most
common human arbovirus infections in the world and
are currently a challenging problem, particularly in the
tropical and subtropical regions of Asia and the Americas.
Infection with DENV may produce symptoms of varying
severity. While access to care, appropriate interventions,
host genetic factors, and previous exposure to DENV are all
known to affect the outcome of the infection, it is not
entirely understood why some individuals develop more
severe disease. It has been hypothesized that the four
dengue serotypes differ in disease severity and clinical
manifestations. This analysis assessed whether there were
significant differences in severity of disease caused by the
dengue serotypes in a pediatric population in Thailand. We
found significant and non-significant correlations between
dengue serotype 2 infection and more severe dengue
disease. We also found that individual serotypes varied in
disease severity between study years, perhaps supporting
the hypothesis that the particular sequences of primary
and secondary DENV infections influence disease severity.
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topenia (platelet count of ,100,000/mm
3); and plasma leakage
evidenced by hemoconcentration $20% increase above the
patient’s baseline, pleural effusion and/or ascites. Cases presenting
with the above criteria as well as either narrow pulse pressure
(,20 mmHg) or profound hypotension were diagnosed with DSS.
Laboratory Methods
Clinical tests, diagnostic serology, and virologic tests were
performed on all study subjects. These measurements included:
complete blood count, hematocrit, ALT, AST, blood group,
dengue IgG/IgM antibody, hemagglutination inhibition, dengue
RT-PCR
[30], and virus isolation by mosquito inoculation. Viruses
isolated in mosquitoes were serotyped using an antigen capture
EIA
[29]. Differences between the serotype results from RT-PCR
and EIA were extremely rare and resolved with repeat testing.
Statistical Analysis
Only patients with confirmed dengue illness were included in
the analysis. Data were entered using FoxPro for Windows
software and analysis was performed using Stata/IC 10.0 for
Macintosh
[31]. Crude odds ratios (OR) and their 95% confidence
intervals (CI) were calculated. Student’s t test was used to compare
mean values of variables and Pearson’s x
2 test was used to
determine significance. Unadjusted and adjusted analyses were
performed using univariate and multivariate logistic regression to
assess the association of DHF (of any grade) with serotype while
controlling for sex, age, blood type, and serological response
profile. Multivariate logistic regression was performed by building
progressively larger models including Model A (serotype), Model B
(serotype, sex), Model C (serotype, sex, age), Model D (serotype,
sex, age, primary/secondary infection), and Model E (serotype,
sex, age, primary/secondary infection, blood type). Models
including interactions between serotypes and all blood types were
also assessed
[32]. Multinomial logistic regression was used to assess
the association between the covariates in models A–E and the
multinomial outcome of each case as either DF, DHF I, DHF II,
DHF III, or DHF IV (5 possible outcomes).
Additional regressions were performed to investigate the
association between severe clinical manifestations and serotype.
The parameters included in the analysis were pleural effusion/
PEI, ascites, hemoconcentration, and plasma leakage, a summary
variable considered positive if any of ascites, pleural effusion, or
hemoconcentration was present. A two-tailed P-value ,0.05 was
considered statistically significant.
Results
Patient Demographics
Among the 457 children included in this study, ages ranged
from 18 months to 15 years with a mean (SD) age of 8.6 (3.0) years
(Table 1). The mean (SD) age of children diagnosed with DF was
8.5 (3.0) years, while the mean (SD) age for children with DHF was
8.7 (3.1) years (p=ns). Based on results from graphical (Figure 1)
and exploratory data analyses, we included in our candidate
models an indicator variable to control for whether subjects were
greater or less than 5.4 years of age. The indicator variable
allowed us to estimate different effects of increasing age among
those less than 5.4 years of age compared to those older. Figure 1
suggests that, before 5.4 years of age, the risk of DHF declines
with increasing age, while after 5.4 years of age the risk increases
with increasing age. Males and females were represented with
comparable frequency (55.5% male).
Serological Response Profile
There were statistically significant differences in disease severity
among patients with primary and secondary infections. Of the 457
cases with serological data, 14% of patients with primary infections
had DHF, whereas 43% with secondary infections had DHF (OR
4.71 95% CI 2.6, 8.6; Table 1). We also found that the severity of
DHF was associated with secondary infection. The odds ratio
estimated for secondary infection increased with the severity of
DHF; secondary infections were more strongly associated with
DHF grades III and IV (15.7 95% CI 2.1, 118.3), than either DHF
grade I (OR 2.8 95% CI 0.9, 8.5) or DHF grade II (OR 4.9 95%
CI 2.3, 10.4).
Serotypes
DENV-1 was the most commonly found serotype in study
subjects, followed by DENV-3, DENV-2, and DENV-4; the eight
Table 1. Virological and demographic data by disease severity.
Variable DF (n=289) DHF (n=169) p-value Crude OR for DHF Adjusted OR for DHF
n (%) n (%) (95% CI) (95% CI)*
Serotype 1 108 (67) 54 (33) . 1 1
Serotype 2 58 (57) 44 (43) 0.652 1.5 (0.9, 2.5) 1.2 (0.7, 2.0)
Serotype 3 75 (61) 48 (39) 1 1.3 (.8, 2.1) 1.5 (0.9, 2.4)
Serotype 4 44 (69) 20 (31) 1 0.9 (0.5, 1.7) 0.6 (0.3 1.2)
Male 159 (63) 95 (37) . 1 1
Female 130 (64) 74 (36) 0.804 1.0 (0.7, 1.4) 1.0 (0.6, 1.4)
Mean age in years (SD) 8.5 (3.0) 8.7 (3.1) 0.382 . .
age . . . 1.0 (1.0, 1.0) 1.0 (0.9, 1.0)
age.65 months . . . 1.0 (1.0, 1.0) 1.0 (1.0, 1.1)
Primary infection 86 (86) 14 (14) . 1 1
Secondary infection 202 (57) 155 (43) ,0.001 4.7 (2.6, 8.6) 5.1 (2.7, 9.5)
AB blood type 12 (4) 16 (10) 0.022 2.4 (1.1, 5.2) 3.0 (1.3, 7.0)
*We adjusted for sex, age, blood type, and serological response profile.
doi:10.1371/journal.pntd.0000617.t001
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this analysis (Table 2). When adjusting for primary/secondary
serological response profile, there was no association found
between DHF and serotype (p=0.295 by Pearson’s x
2 test). When
considering a multinomial response (DF, and the four grades of
DHF), DENV-2 was found to be statistically significantly
associated with increased odds of DHF grade I compared to DF
(OR 2.9 95% CI 1.1, 8.0) when compared to DENV-1. None of
the DHF grades were associated with DENV-2 when compared to
either DENV-3 or DENV-4. Though not statistically significant,
DENV-2 was consistently associated with an increased odds of
DHF total (OR 1.5 95% CI 0.9, 2.5), DHF grade II (OR 1.3 95%
CI 0.7, 2.4) and DHF grades III and IV (OR 1.4 95% CI 0.5, 3.6)
compared to DENV-1. Controlling for a primary or secondary
serological response, age, season and sex, DHF grade I was again
associated with DENV-2 (OR 3.1 95% CI 1.0, 9.4) compared to
DENV-1.
DENV-1 (28%) and DENV-3 (33%) were more often associated
with primary DENV infections than DENV-2 (9%, OR 0.2 95%
CI 0.08, 0.5) and DENV-4 (3%, OR 0.06 95% CI 0.01, 0.3).
Restricting analysis to secondary cases, we found DENV-2 and
DENV-3 to be twice as likely to result in DHF rather than DF
compared to DEN-4 (p=0.05, p=0.04, respectively).
In aggregate across all serotypes, disease was significantly less
severe during 1999 (OR 0.3 95% CI 0.1, 0.8), 2000 (OR 0.2 95%
CI 0.1, 0.7), 2004 (OR 0.4 95% CI 0.2, 0.1), and 2005 (OR 0.3
95% CI 0.1,0.8) compared to 1994, the year with the highest
percentage of severe cases (Table 2). This is not associated with
differences in the serotype distribution in these years compared to
others.
As was shown previously with a subset of these data, AB blood
type showed a significant association with DHF (OR 2.8 95% CI
1.2, 6.3)
[32]. There were no significant modification effects when
analysis was performed to investigate the interactions between
serotypes and blood types.
Clinical Manifestations
Secondary DENV infection was associated with severe mani-
festations of pleural effusion/PEI, ascites, and thrombocytopenia;
it was not statistically significantly associated with hemoconcen-
Table 2. Serotype-specific data.
Year DENV-1 DENV-2 DENV-3 DENV-4 Totals
#
p-value
1 p-value
##
DF DHF DF DHF DF DHF DF DHF DF DHF
(n=108) (n=54) (n=58) (n=44) (n=75) (n=48) (n=44) (n=20) (n=289) (n=169)
n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % ) n( % )
1994 8 (73) 3 (27) 3 (38) 5 (63) 2 (29) 5 (71) 5 (50) 5 (50) 18 (50) 18 (50) ref 0.02
1995 7 (78) 2 (22) 2 (25) 6 (75)
** 5 (71) 2 (29) 0 (0) 1 (100) 14 (56) 11 (44) NS 0.07
1996 9 (56) 7 (44) 6 (40) 9 (60) 14 (64) 8 (36) 2 (100) 0 (0) 32 (57) 24 (43) NS 0.05
1997 17 (61) 11 (39) 11 (55) 9 (45) 21 (60) 14 (40) 0 (0) 0 (0) 49 (59) 34 (41) NS 0.06
1999 8 (80) 2 (20) 2 (67) 1 (33) 14 (78) 4 (22)
{ 1 (100) 0 (0) 25 (78) 7 (22) 0.02 ref
2000 12 (86) 2 (24)
* 6 (75) 2 (25) 4 (80) 1 (20) 2 (67) 1 (33) 24 (77) 7 (23) 0.02 NS
2001 13 (68) 6 (32) 11 (58) 8 (42) 3 (50) 3 (50) 0 (0) 1 (100) 27 (60) 18 (40) NS 0.09
2002 7 (64) 4 (36) 7 (70) 3 (30) 0 (0) 1 (100) 0 (0) 0 (0) 15 (63) 9 (38) NS NS
2004 10 (53) 9 (47) 5 (100) 0 (0) 1 (100) 0 (0) 19 (83) 4 (17)
{ 36 (72) 14 (28) 0.04 NS
2005 5 (63) 3 (38) 4 (80) 1 (20) 5 (83) 1 (17) 11 (85) 2 (15) 25 (78) 7 (22) 0.02 ref
2006 12 (71) 5 (29) 1 (100) 0 (0) 6 (40) 9 (60) 4 (40) 6 (60) 24 (55) 20 (46) NS 0.03
primary 40 (87) 6 (13) 9 (100) 0 (0) 33 (81) 8 (20) 2 (100) 0 (0) 86 (86) 14 (14) . .
secondary 68 (59) 48 (41) 48 (52) 44 (48) 42 (51) 40 (49) 42 (68) 20 (32) 202 (57) 155 (43) . .
Significant differences between study years within a serotype include:
*p=0.05 compared to 2004.
**p=0.02 compared to 2004.
{p=0.03 compared to 2006.
{p=0.03 compared to 2006. Significant differences in disease severity between study years overall include:
1most severe study year is used as reference.
##least severe study year is used as reference.
#Discrepancies in totals are due to the 7 cases that were not serotyped and the single case that did not receive a serological response profile.
doi:10.1371/journal.pntd.0000617.t002
Figure 1. Smoothed lowess plot of odds of DHF vs. age. Odds of
DHF upon dengue illness as a function of age (18 months to 15 years).
Those not experiencing DHF were diagnosed with DF. A transition point
of 5.4 years used to define an indicator variable in regression analyses is
shown on the x-axis.
doi:10.1371/journal.pntd.0000617.g001
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ascites and pleural effusion index (PEI) with DENV-2 (OR 2.1
95% CI 1.0, 4.1; mean PEI was 1.8 times greater for DENV-2;
95% CI 1.1, 3.1); however, multivariate analyses, when controlling
for sex, age, study year, and serological response profile, did not
(OR 1.5 95% CI 0.7, 3.1; OR 1.5 95% CI 0.8, 2.6). There were no
statistically significant associations of the presence of pleural
effusion, hemoconcentration, or thrombocytopenia with serotype
of infection in univariate or multivariate analyses.
Discussion
The results of this prospective observational, single-site study of
pediatric dengue showed a significant association between DENV-
2 and DHF grade I and nonsignificant associations with other
grades of DHF. DENV-2 was also associated with the presence of
ascites and larger pleural effusions index. Additionally, we
confirmed the previously reported associations between secondary
serologic response and DHF as well as a more severe grade of
DHF.
Other reports have suggested a correlation between serotype
and disease severity. Studies in Thailand and Taiwan found a
significant correlation between DENV-2 and greater disease
severity
[5,9]. While we found that DENV-2 was most likely to
cause DHF (44%) and DENV-4 was less likely (31%) this finding
was not statistically significant.
Statistical analysis showed that clinical manifestations of ascites
and larger pleural effusions were significantly associated with
DENV-2. However, upon adjustment for primary or secondary
infection, this association became non-significant. We had limited
ability to assess the independent effects of DENV-2 and primary/
secondary serological response on the risk of ascites and pleural
effusion because such a high percentage of DENV-2 infections
were secondary (92%). Several reports have suggested differences
in clinical manifestations with distinct dengue serotypes. Vaughn et
al., using a subset of data included in this analysis, reported that
from 1994–1996, there were more cases of pleural effusion in
DENV-2 infections than those infected with the other three
serotypes
[9]. This was not found to be statistically significant in
this larger dataset using multivariate analysis incorporating other
factors including secondary infection, but the volume of effusions
was still greater with DENV-2 as in the earlier study. Additionally,
Balmaseda et al., found an increased incidence of plasma leakage
and thrombocytopenia among those with DENV-1 as compared
to DENV-2 infections in Nicaragua from 1999–2001 and during
an outbreak in 2003
[33]; however, these findings are limited by the
short observation period.
Data from this study support the finding that, among those who
presented for medical attention, dengue cases caused by DENV-2
and DENV-4 are overwhelmingly secondary infections
[34],a n d
there were no cases of DHF caused by primary DENV-2 and
DENV-4. This suggests that DENV-1 and DENV-3 are more
pathogenic without immune priming from other serotypes. It has
been reported that DENV-4 causes more mild disease in primary
DENVinfections
[21,35].WefoundthatDENV-2andDENV-3were
more likely to cause DHF as secondary infections than DENV-4.
Importantly, this analysis found significantly less severe disease
in the study population during 1999, 2000, 2004, and 2005,
regardless of viral serotype. (Table 2) Several mechanisms could be
responsible for this observation. It is hypothesized that the
sequence of serotype infections (both first and second infections)
influences disease severity. These years may have been less severe
because fewer people had some specific dengue virus immunity
that placed them at risk of severe disease upon infection with the
predominant viruses circulating those years. It is possible that
cross-immunity to viruses circulating in prior years affected disease
severity. Finally, there may be significant variation in the risk of
severe illness upon infection between viruses within serotypes.
The greatest limitation in this study was that all subjects
presented for medical attention, but many who would have been
treated as outpatients were admitted for the purposes of this study.
By including only patients who seek medical attention, those with
milder disease or asymptomatic infections are missed. Addition-
ally, with a limited sample size, estimating models with large
numbers of covariates is difficult. Further, only a Thai population
was captured; as this study group was ethnographically homog-
enous, it may not be appropriate to apply the study findings in
clinical settings to ethnically diverse populations. Another
consideration is that QSNICH is in the urban center of Bangkok
and may represent only one of several ecological niches for the
dengue vector. However, pediatricians caring for children with
suspected dengue infections at the QSNICH are recognized as
experts in the management of clinical dengue; consequently,
parents from Bangkok and the surrounding area are likely to seek
care at QSNICH.
Strengths of the study include the long 11–year data collection
period, with virus isolation and serotype identification in 98.5% of
Table 3. Clinical manifestations.
Manifestations DENV-1 DENV-2 DENV-3 DENV-4 Total
Primary
Infection
Secondary
Infection
Crude OR for Secondary
Infection in Patients with
vs. without Manifestations
n (%) n (%) n (%) n (%) n (%) n (%) n (%) (95% CI, p-value)
Ascites 18 (11
*) 21 (21) 15 (12) 9 (14) 63 (14) 5 (8) 58 (92) 3.7 (1.4–9.5, 0.007)
Hemoconcentration 65 (40) 46 (45) 52 (42) 30 (47) 195 (43) 36 (19) 159 (82) 1.4 (0.9–2.3, 0.128)
Thrombocytopenia 99 (61) 62 (61) 74 (60) 34 (53) 274 (60) 36 (13) 238 (87) 3.6 (2.2–5.7, ,0.001)
Plasma leakage 86 (53) 63 (62) 72 (59) 36 (57) 261 (57) 46 (18) 215 (82) 1.8 (1.2–2.8, 0.011)
Pleural effusion 55 (34) 41 (40) 45 (37) 23 (36) 167 (37) 15 (9) 152 (91) 4.2 (2.3–7.6, 0.00)
Mean Pleural Effusion
Index (PEI)
5.1 8.4
{ 5 4.3 5.7 0.6 7.1
{
*Percent of DENV-1 cases with ascites.
{Mean pleural effusion indexes (PEI) were significantly higher among DENV-2 compared to DENV-1.
{Mean pleural effusion indexes (PEI) were significantly higher among secondary infections as compared to primary infections.
doi:10.1371/journal.pntd.0000617.t003
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allowed for the representation of all four serotypes, thus providing
data for a more complete analysis. Furthermore, the care and
evaluations were performed by the same attending physician
throughout the study, reducing the possibility of recording and
diagnostic errors and inconsistencies. Lastly, the diagnoses were
evaluated in greater depth than standard clinical practice.
In this analysis we found some significant correlations between
DENV-2 infection and more severe dengue disease, although
other associations were not statistically significant. The increased
odds of DHF grade I illnesses among DENV-2 infections
compared to DENV-1 is difficult to explain, given we did not
observe an increase among higher grades of DHF. While this
result might be spurious, it was observed in several models,
adjusting for slightly different sets of covariates. Overall, the
evidence for DENV-2 infections being more severe is a suggestive
trend rather than strong evidence. We did find that individual
serotypes varied in disease severity between study years, perhaps
supporting the hypothesis that the sequence of serotype infections
influences the disease severity.
Acknowledgments
Disclaimer: The opinions or assertions contained herein are the private
views of the authors, and are not to be construed as official, or as reflecting
the views of the Department of the Army, the Department of Defense, or
the National Institute of Health.
Author Contributions
Analyzed the data: JRF. Wrote the paper: JRF. Analyzed and interpreted
data: JRF. Drafted and revised manuscript: JRF. Contributed to original
study design and interpretation of data, and manuscript revision: DVG SK.
Participated in the interpretation of data and manuscript revision: SJT AS
I-KY RGJ SG ALR. Participated in the analysis, interpretation of data,
and manuscript revision: DATC.
References
1. Ng CF, Lum LC, Ismail NA, Tan LH, Tan CP (2007) Clinicians’ diagnostic
practice of dengue infections. J Clin Virol 40(3): 202–206.
2. World Health Organization (1997) Dengue haemorrhagic fever: Diagnosis,
treatment, prevention, and control. Geneva: WHO. 84 p.
3. Gubler DJ (1999) Dengue viruses (flaviviridae). In: AllanGranoff,
Robert G.Webster, eds. Encyclopedia of Virology. Oxford: Elsevier. 375–384.
4. Gubler DJ (1998) Dengue and dengue hemorrhagic fever. Clin Microbiol Rev
11(3): 480–496.
5. Chen RF, Yang KD, Wang L, Liu JW, Chiu CC, et al. (2007) Different clinical
and laboratory manifestations between dengue haemorrhagic fever and dengue
fever with bleeding tendency. Trans R Soc Trop Med Hyg 101(11): 1106–1113.
6. White NJ (1999) Variation in virulence of dengue virus. Lancet 354(9188):
1401–1402.
7. Stephens HA, Klaythong R, Sirikong M, Vaughn DW, Green S, et al. (2002)
HLA-A and -B allele associations with secondary dengue virus infections
correlate with disease severity and the infecting viral serotype in ethnic Thais.
Tissue Antigens 60(4): 309–318.
8. Acioli-Santos B, Segat L, Dhalia R, Brito CAA, Braga-Neto UM, et al. (2008)
MBL2 gene polymorphisms protect against development of thrombocytopenia
associated with severe dengue phenotype. Human Immunology 69(2): 122–128.
9. Vaughn DW, Green S, Kalayanarooj S, Innis BL, Nimmannitya S, et al. (2000)
Dengue viremia titer, antibody response pattern, and virus serotype correlate
with disease severity. J Infect Dis 181(1): 2–9.
10. Thein S, Aung MM, Shwe TN, Aye M, Zaw A, et al. (1997) Risk factors in
dengue shock syndrome. Am J Trop Med Hyg 56(5): 566–572.
11. Burke DS, Nisalak A, Johnson DE, Scott RM (1988) A prospective study of
dengue infections in Bangkok. Am J Trop Med Hyg 38(1): 172–180.
12. Graham RR, Juffrie M, Tan R, Hayes CG, Laksono I, et al. (1999) A
prospective seroepidemiologic study on dengue in children four to nine years of
age in Yogyakarta, Indonesia I. studies in 1995–1996. Am J Trop Med Hyg
61(3): 412–419.
13. Endy TP, Chunsuttiwat S, Nisalak A, Libraty DH, Green S, et al. (2002)
Epidemiology of inapparent and symptomatic acute dengue virus infection: A
prospective study of primary school children in Kamphaeng Phet, Thailand.
Am J Epidemiol 156(1): 40–51.
14. Guzman MG, Kouri G, Valdes L, Bravo J, Alvarez M, et al. (2000)
Epidemiologic studies on dengue in Santiago de Cuba, 1997. Am J Epidemiol
152(9): 793–9; discussion 804.
15. Sierra B, Alegre R, Perez AB, Garcia G, Sturn-Ramirez K, et al. (2007) HLA-A,
-B, -C, and -DRB1 allele frequencies in Cuban individuals with antecedents of
dengue 2 disease: Advantages of the Cuban population for HLA studies of
dengue virus infection. Hum Immunol 68(6): 531–540.
16. Guzman MG (2005) Global voices of science. deciphering dengue: The Cuban
experience. Science 309(5740): 1495–1497.
17. Halstead SB, Streit TG, Lafontant JG, Putvatana R, Russell K, et al. (2001)
Haiti: Absence of dengue hemorrhagic fever despite hyperendemic dengue virus
transmission. Am J Trop Med Hyg 65(3): 180–183.
18. Gibbons RV, Vaughn DW (2002) Dengue: An escalating problem. BMJ
324(7353): 1563–1566.
19. Guzman MG, Kouri G (2003) Dengue and dengue hemorrhagic fever in the
Americas: Lessons and challenges. J Clin Virol 27(1): 1–13.
20. Rico-Hesse R (2003) Microevolution and virulence of dengue viruses. Adv Virus
Res 59: 315–341.
21. Nisalak A, Endy TP, Nimmannitya S, Kalayanarooj S, Thisayakorn U, et al.
(2003) Serotype-specific dengue virus circulation and dengue disease in Bangkok,
Thailand from 1973 to 1999. Am J Trop Med Hyg 68(2): 191–202.
22. Russell PK, Yuill TM, Nisalak A, Udomsakdi S, Gould DJ, et al. (1968) An
insular outbreak of dengue hemorrhagic fever. II. virologic and serologic studies.
Am J Trop Med Hyg 17(4): 600–608.
23. Sangkawibha N, Rojanasuphot S, Ahandrik S, Viriyapongse S, Jatanasen S, et
al. (1984) Risk factors in dengue shock syndrome: A prospective epidemiologic
study in Rayong, Thailand. I. the 1980 outbreak. Am J Epidemiol 120(5):
653–669.
24. Halstead SB (1980) Immunological parameters of togavirus disease syndromes.
In: Schlesinger RW, ed. The togaviruses: biology, structure, replication. New
York: Academic Press. 107–73.
25. Kochel TJ, Watts DM, Gozalo AS, Ewing DF, Porter KR, et al. (2005) Cross-
serotype neutralization of dengue virus in aotus nancymae monkeys. J Infect Dis
191(6): 1000–1004.
26. Kochel TJ, Watts DM, Halstead SB, Hayes CG, Espinoza A, et al. (2002) Effect
of dengue-1 antibodies on American dengue-2 viral infection and dengue
haemorrhagic fever. Lancet 360(9329): 310–312.
27. Kalayanarooj S, Vaughn DW, Nimmannitya S, Green S, Suntayakorn S, et al.
(1997) Early clinical and laboratory indicators of acute dengue illness. J Infect
Dis 176(2): 313–321.
28. Srikiatkhachorn A, Krautrachue A, Ratanaprakarn W, Wongtapradit L,
Nithipanya N, et al. (2007) Natural history of plasma leakage in dengue
hemorrhagic fever: A serial ultrasonographic study. Pediatr Infect Dis J 26(4):
283–90; discussion 291–2.
29. Innis BL, Nisalak A, Nimmannitya S, Kusalerdchariya S, Chongswasdi V, et al.
(1989) An enzyme-linked immunosorbent assay to characterize dengue infections
where dengue and japanese encephalitis co-circulate. Am J Trop Med Hyg
40(4): 418–427.
30. Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV (1992)
Rapid detection and typing of dengue viruses from clinical samples by using
reverse transcriptase-polymerase chain reaction. J Clin Microbiol 30(3):
545–551.
31. Stata Corporation (2007) Stata statistical software: Release 10.
32. Kalayanarooj S, Gibbons RV, Vaughn D, Green S, Nisalak A, et al. (2007)
Blood group AB is associated with increased risk for severe dengue disease in
secondary infections. J Infect Dis 195(7): 1014–1017.
33. Balmaseda A, Hammond SN, Perez L, Tellez Y, Saborio SI, et al. (2006)
Serotype-specific differences in clinical manifestations of dengue. Am J Trop
Med Hyg 74(3): 449–456.
34. Anantapreecha S, Chanama S, A-nuegoonpipat A, Naemkhunthot S, Sa-
Ngasang A, et al. (2005) Serological and virological features of dengue fever and
dengue haemorrhagic fever in Thailand from 1999 to 2002. Epidemiol Infect
133(3): 503–507.
35. Klungthong C, Zhang C, Mammen MP, Jr., Ubol S, Holmes EC (2004) The
molecular epidemiology of dengue virus serotype 4 in Bangkok, Thailand.
Virology 329(1): 168–179.
Serotype Differences and Dengue Hemorrhagic Fever
www.plosntds.org 6 March 2010 | Volume 4 | Issue 3 | e617